be strong, page-13

Firstly, I dont see a credit risk factor for EMS.

Secondly, we wont know until mid-december whether the report will be released this year or not.

But basically, by the start of december the market will well and truly IMO start pricing in a positive trial outcome being released shortly after that.

That IMO will push the SP far higher than 5c by the time the report is released.

At 5c the market cap would be $30m which IMO is too low for a company on the verge of announcing the results of a Phase III trial.

And the above does incorporate any positive BP resolution which IMO could add 50%+ to the current SP pretty quickly.